Renaissance Technologies LLC Has $5.04 Million Holdings in AnaptysBio, Inc. $ANAB

Renaissance Technologies LLC lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 19.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 90,900 shares of the biotechnology company’s stock after purchasing an additional 14,600 shares during the quarter. Renaissance Technologies LLC owned 0.31% of AnaptysBio worth $5,041,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Smartleaf Asset Management LLC lifted its position in shares of AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 821 shares during the period. Larson Financial Group LLC raised its stake in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in AnaptysBio by 24.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 263 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in AnaptysBio by 987.3% in the 4th quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 1,560 shares during the period.

Wall Street Analyst Weigh In

ANAB has been the subject of several analyst reports. Zacks Research cut shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Barclays lifted their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. HC Wainwright started coverage on shares of AnaptysBio in a research report on Wednesday, June 10th. They set a “buy” rating and a $95.00 price objective for the company. Weiss Ratings cut AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Finally, Leerink Partners set a $90.00 target price on AnaptysBio in a report on Friday, May 15th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.00.

AnaptysBio Trading Down 0.4%

ANAB stock opened at $54.77 on Friday. The firm has a 50-day moving average price of $57.46 and a 200-day moving average price of $58.05. AnaptysBio, Inc. has a 12 month low of $11.40 and a 12 month high of $72.36. The stock has a market capitalization of $1.62 billion, a P/E ratio of -50.71 and a beta of 0.72.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The company had revenue of $25.56 million for the quarter, compared to the consensus estimate of $18.86 million. As a group, equities analysts predict that AnaptysBio, Inc. will post -1.35 EPS for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.